Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Adapting to a pandemic: small changes can make a big difference

By Peter Impey

- PMLiVE

Eli Lilly’s COVID-19 antibody trial paused due to safety issue

Company has voluntarily paused study amid safety review

- PMLiVE

Shionogi’s novel antibiotic trial data published in The Lancet

Data from APEKS-NP and CREDIBLE-CR studies published

- PMLiVE

Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout

Patients treated in intensive care met survival threshold in open-label study

- PMLiVE

Mallinckrodt files for bankruptcy protection in the US

Bankruptcy filing will reduce debts related to legal liabilities

- PMLiVE

J&J halts COVID-19 vaccine study after unexplained participant illness

Company convened data and safety monitoring board to review event

- PMLiVE

Bombarded with information – the challenge of crowded digital channels

Chris Ross explores the pursuit of communications excellence in a world of noise

- PMLiVE

NORD Rare Diseases Breakthrough Summit

Gavin Jones, Director of Rare Disease, provides his thoughts on last week’s NORD Breakthrough Summit and a collective need to reduce inequalities in rare disease

OPEN Health

- PMLiVE

Lucid Group are keeping wellness front of mind

It's important to make sure that people are supported and encouraged to practice self-care throughout the year. This is why Lucid Group has been reminding its teams of the LucidBeing...

Lucid Group Communications Limited

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Target action date for FDA decision is due on 15 November

- PMLiVE

UK scientists begin testing BCG vaccine for severe COVID-19 protection

Researchers believe shot could help to protect against severe COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links